Access cutting-edge myelofibrosis treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access myelofibrosis specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related myelofibrosis treatment provided free
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.
Sponsor: Telios Pharma, Inc.
Check if you qualify for this myelofibrosis clinical trial in Birmingham, AL
If you're searching for myelofibrosis treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myelofibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.